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Rotenone is a naturally occurring insecticide that inhibits mitochondrial complex I and leads to neurochemical
and neuropathological deficits closely resembling those in Parkinson’s disease (PD). Deficits include loss of
dopaminergic neurons (DAn) in the substantia nigra pars compacta (SNpc), decreased dopamine levels and
aggregation of misfolded alpha-synuclein (p129). In rat models of rotenone-induced parkinsonism, the pro
gression of neuronal injury has been associated with activation of microglia and astrocytes. However, these
neuroinflammatory changes have been challenging to study in mice, in part because the systemic rotenone
exposure model utilized in rats is more toxic to mice. To establish a reproducible murine model of rotenoneinduced PD, we therefore investigated the progression of neuroinflammation, protein aggregation and DAn
loss in C57Bl/6 mice by exposing animals to 2.5 mg/kg/day rotenone for 14 days, followed by a two-week period
where neuroinflammation is allowed to progress. Our results indicate that initial cellular dysfunction leads to
increased formation of proteinase K-resistant p129 aggregates in the caudate-putamen and SNpc. Clearance of
these aggregates was region- and cell type-specific, with the early appearance of reactive astrocytes coinciding
with accumulation of p129 in the SNpc. Phagocytic microglial cells containing p129 aggregates were observed
proximal to p129+ DAn in the SNpc. The majority of neuronal loss in the SNpc occurred during the two-week
period after rotenone exposure, subsequent to the peak of microglia and astrocyte activation, as well as the
peak of p129 aggregation. A secondary peak of p129 coincided with neurodegeneration at later timepoints. These
data indicate that systemic exposure to rotenone in C57Bl/6 mice causes progressive accumulation and regional
spread of p129 aggregates that precede maximal loss of DAn. Thus, activation of glial cells and aggregation of
p129 appear to drive neuronal loss following neurotoxic stress imposed by exposure to rotenone.

1. Introduction
Parkinson’s disease (PD) is a debilitating movement disorder
affecting the central nervous system (CNS) and the second most common
neurodegenerative disease worldwide (Halliday et al., 2011; Pringsheim
et al., 2014). PD is characterized by loss of dopaminergic neurons (DAn)
in the substantia nigra pars compacta (SNpc), loss of striatal dopamine

(DA), neuroinflammatory activation of glial cells and aggregation of the
phosphorylated form of ⍺-synuclein (phosphor-serine 129/p129)
(Domingues et al., 2020; Grayson, 2016; Rocha et al., 2018; Samii et al.,
2004). There are no disease modifying therapies for PD in part because
of limitations in many of the standard animal models used to study PD
including a lack of critical features relevant to the idiopathic disease
(Radhakrishnan and Goyal, 2018; Schober, 2004). Two widely used

Abbreviations: PD, Parkinson’s Disease; DAn, dopaminergic neurons; SNpc, substantia nigra pars compacta: p129, misfolded α-synuclein; CNS, central nervous
system; DA, dopamine; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 6-OHDA, 6-hydroxydopamine; ROS, reactive oxygen species; SNpr, substantia nigra
pars reticulata; ST, striatum; GP, globus pallidus; C3, complement protein 3; pK, proteinase K; OB, olfactory bulb; M1, activated ameboid pro-inflammatory microglia;
M2, resting/ramified non-inflammatory microglia; A1, activated pro-inflammatory astrocytes; A2, neurotrophic astrocytes.
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models that induce loss of DAn involve administration of the neuro
toxins 1-methyl-4-phenyl-1,2,3,6-tetrahydropyuridine (MPTP) and 6hydroxydopamine (6-OHDA). However, there are aspects of these
models that differ significantly from idiopathic PD, including the
absence of p129-α-Syn aggregates. The progressive development and
spread of p129-α-Syn aggregates leading to Lewy body formation in the
SNpc is the central neuropathological feature of PD but is notoriously
difficult to recapitulate in mice. Because the etiology and progression of
PD is complex, involving genetic, environmental and biological factors,
as well as early and progressive neuroinflammatory changes in glial
cells, additional models that more closely recapitulate the neurological
and pathological deficits observed in PD are necessary to study disease
mechanisms.
It has been shown that systemic administration of pesticides which
inhibit mitochondrial complex I, such as paraquat, maneb and rotenone,
can cause selective loss of DAn in the SNpc and might better recapitulate
certain clinical and pathological features of PD than other neurotoxinbased models (Giasson and Lee, 2000; Johnson and Bobrovskaya,
2015; Kamel et al., 2007; Tanner et al., 2011). Rotenone, in particular, is
a potent systemic inhibitor of mitochondrial complex I that results in
high levels of reactive oxygen species (ROS) and peroxynitrate, as well
as neuroinflammation and progressive accumulation of p129 aggregates
within neuronal dendrites and soma (Betarbet et al., 2000; Cannon et al.,
2009). Rotenone is distributed and used worldwide as a pesticide and
piscicide to reduce crop destruction and invasive fish species (Radad
et al., 2019). Despite evidence that rotenone is associated with increased
risk for PD, it is still used within the USA, Canada and 30 other countries
worldwide (Betarbet et al., 2000; EPA, U, 2007; Guenther, 2011).
Amongst pesticides that inhibit mitochondrial complex I, rotenone
closely models pathological features of PD in both mammalian and nonmammalian species. Non-mammalian models of rotenone-induced
dopaminergic
neurotoxicity
utilizing
Caenorhabditis
elegans,
drosophila, zebrafish and Lymnaea stagnalis have been successful in
achieving DAn cell loss and motor deficits following exposure (Fontana
et al., 2018; Harrington et al., 2010; Hirth, 2010; Vehovszky et al.,
2007). These models allow for rapid, high-throughput screening meth
odologies to investigate potential therapeutics and environmental ex
posures but are limited with respect to the array of motor and non-motor
neurological symptoms that can be modeled, as well as the spread of
p129 aggregates across teleologically relevant brain regions (Dung and
Thao, 2018; Lim, 2010). In contrast, systemic rotenone exposure in
Lewis rats induces behavioral deficits, loss of DAn and formation of
Lewy bodies, closely mirroring the pathological changes seen in PD
(Betarbet et al., 2000; Cannon et al., 2009; Heikkila et al., 1985).
However, it has proven challenging to adapt this model to mice due to
variations in lesion profiles and high mortality rates (Johnson and
Bobrovskaya, 2015). This precludes the advantages offered by a greater
array of transgenic mouse lines to study signaling pathways and mo
lecular mechanisms. Attempts to orally deliver rotenone in mice take at
least two months (Inden et al., 2011; Liu et al., 2017), thus decreasing
throughput for analyzing the therapeutic efficacy of pharmacologic and
genetic interventions in the disease process.
We set out to characterize the efficacy of a 14 day systemic rotenone
model used in Lewis rats by Greenamyre and colleagues (Betarbet et al.,
2000; Cannon et al., 2009; Sherer et al., 2003) in eliciting PD-like
neuropathological changes in mice, with particular emphasis on the
capacity of this route of administration to promote progressive neuro
inflammation and the formation of p129 aggregates. The key neuro
pathological features examined within lesioned brain regions included
vacuolation of nerve cells, neuronal loss within the basal midbrain
spatially progressing in a latero-temporal manor, glial cell activation
and the accumulation of p129 aggregates within neurons. These changes
were examined weekly across entire serial brain sections using scanning
microscopy starting at the conclusion of the rotenone dosing period at 2
weeks through the end of the study at 4 weeks. This approach permitted
the quantification of both regional and temporal patterns of gliosis,

neuronal loss and p129 across multiple brain regions throughout the
entire dosing and lesioning period. The results of this analysis revealed
distinct patterns of neuropathology with maximal loss of DAn occurring
nearly two weeks after the end of rotenone administration (4 WPI), after
the peak of glial activation and coinciding with p129 aggregation. These
data suggest that induction of p129 is a stress response to rotenoneinduced mitochondrial dysfunction and that glial inflammatory re
sponses are a key potentiator of both p129 aggregation and neuronal
injury in this rotenone model of PD in mice.
2. Materials and methods
2.1. Animals and in vivo imaging
All animal protocols were approved by the Institutional Animal Care
and Use Committee at Colorado State University (IACUC), mice were
handled in compliance with the PHS Policy and Guide for the Care and
Use of Laboratory Animals and procedures were performed in accor
dance with National Institutes of Health guidelines. Mice were housed in
microisolator cages (3–4 animals per cage), kept on a 12-h light/dark
cycle and had access to both food and water ad libitum. Male and female
C57Bl/6 background mice were used in studies at 2 months of age (n =
12/control, n = 21/rotenone). Male and female homozygous Tg(HIVEGFP,luc)8Tsb/J mice were obtained from The Jackson Laboratory
(Stock No. 027529, Bar Harbor ME) and bred to homozygosity onto a
C57Bl/6 background for use in this study (n = 8/control, n = 9/rote
none). For imaging luciferase reporter activity in situ, Tg(HIV-EGFP,luc)
8Tsb/J mice (2 WPI: n = 8 control, n = 9 rotenone; 3 WPI: n = 7 control,
n = 7 rotenone; 4 WPI: n = 6 control, n = 5 rotenone) were anesthetized
at weekly timepoints following exposure with rotenone (2 WPI) and
then given a subcutaneous dose of luciferin substrate (150 mg/kg) to the
dorsal cervical spine 17 min prior to imaging. Exposure time was kept
consistent for all animals. Animals from. Living Image Software was
used to obtain and analyze images on the IVIS Spectrum in vivo imaging
system utilizing epi-illumination 3D diffuse fluorescence tomography.
2.2. Rotenone preparation and dosing
Rotenone was first prepared in a 50× stock solution that was diluted
in 100% dimethyl sulfoxide (DMSO). The rotenone solution was then
diluted in medium-chain triglyceride, Miglyol 812 (Cannon et al., 2009)
to obtain final working concentrations of 2.5 mg/kg at a dosage of 2 μL/
g body weight in 98% miglyol and 2% DMSO. The rotenone was pre
pared fresh every other day. Rotenone powder was pipetted until thor
oughly dissolved into DMSO. The stock solution was aliquoted into
amber septa vials within a − 20 ◦ C freezer to avoid contact with light.
The head space of the vial was purged with nitrogen to prevent oxidation
of the compound. The optimal concentration of rotenone was deter
mined from a dosing regimen consisting of intraperitoneal dosing daily
for 14 days. Male and female C57Bl/6 mice (n = 4/control group/timepoint, n = 7/rotenone group/time-point) were injected daily for 14 days
with a dose of 2 μL/g weight. Mice were weighed daily before injection
to determine the appropriate dosing amount. The rotenone/miglyol was
carefully measured using a 50 μL Hamilton syringe and then transferred
to an insulin syringe with permanently attached needle which was used
to administer the volume of solution. Control animals received in
jections of miglyol only. Hamilton syringes were cleaned every-day after
use to prevent precipitation buildup within the needle. The syringe and
plunger were submersed in 10% bleach for a duration of 10 min, then
70% ethanol was aspirated into the syringe followed by sterile water.
The plunger was removed from the syringe and the instrument was
allowed to air dry for 24 h.
To identify the optimal dose of rotenone to induce loss of DAn, pilot
studies were conducted in which mice were administered several con
centrations of rotenone at different dosing schedules. Rotenone was
dissolved in 100% miglyol 812 as described above. The final dosage used
2
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in subsequent studies was determined by quantitative analysis of DAn
numbers within the SNpc using design-based stereology and scanning
fluorescence microscopy. Regions of interest (ROI) were mapped for the
ST and the SNpc. Male and female C57Bl/6 mice (n = 4/group) were
injected intraperitoneally with 2.0 mg/kg/day, 2.5 mg/Kg/day, 3.0 mg/
kg/day and 1.4 mg/kg twice daily. Twice daily dosing at 1.4 mg/Kg was
highly toxic and omitted from further evaluation. Mice were terminated
14 days after the initial rotenone dose and neurodegeneration was
assessed. Based upon initial results and minimal mortalities, a dose of
2.5 mg/Kg/day was selected for use in the 4-week study (n = 4 animals/
control groups, n = 7 animals/rotenone groups).

coverslips in ProLong Gold Antifade hard set mounting medium and
stored at 4 ◦ C until time of imaging.
2.6. Histological staining and examination
Paraffin embedded brain tissue was sectioned at 6 μm thickness and
mounted to poly-ionic slides (Histotox Labs, Boulder, CO). Sections were
deparaffinized and stained with hematoxylin and eosin. Each section
was analyzed at a 10× and 40× magnification using an Olympus IX71
microscope (Center Valley, PA) with Retiga 2000R (Qimaging, Surrey,
BC, Canada) and Qcolor3 (Olympus) camera and Slidebook software
(v6.0, Intelligent Imaging Innovations, Inc., Denver, CO) for image
acquisition and analysis. Stained SN and ST sections were investigated
and read by a board-certified veterinary pathologist who was blinded to
all groupings.

2.3. Open field behavioral analysis
Open field activity was assessed using the Versamax behavioral
system with an infrared beam grid detection array (Accuscan In
struments, Inc., Columbus, OH). Mice were monitored for 5 min under
low ambient light in the presence of white noise. Animals were preconditioned to the chambers the day before exposure started. The ani
mals were recorded 1 h prior to initial injection (0 DPI) to establish a
baseline. Several behavioral assessments were performed at weekly
timepoints (1 WPI, 2 WPI, 3 WPI and 4 WPI). Multiple behavioral pa
rameters were obtained and analyzed using Versadat Software (Accus
can Instruments, Inc.) including rearing number, center time, margin
time and rest time. We previously reported that these locomotor and
behavioral parameters are accurate determinants of basal ganglia
function associated with loss of striatal DA (Liu et al., 2006; Moreno
et al., 2009). Data is reported as change from baseline (0 DPI) behavioral
assessment. (n = 10/control, n = 14/rotenone).

2.7. Unbiased stereological neuronal counting and striatal terminal
analysis
Quantification of neurons was adapted from those previously re
ported (Bantle et al., 2019; Sadasivan et al., 2015; Tapias and Green
amyre, 2014). In brief, every 20th tissue section was selected for staining
and counted, resulting in six sections per animal being counted. The
studies described here were conducted blindly by a single investigator.
Images were captured using an automated Olympus BX63 fluorescence
microscope equipped with a Hamamatsu ORCA-flash 4.0 LT CCD camera
and collected using Olympus CellSens software (v1.15). Quantitative
analysis was performed on dually labeled fluorescent images generated
by montage imaging of the entire coronal brain section by compiling
single 100× magnification images acquired by using an Olympus XApochromat 10× air objective (0.40 N.A.). One hemisphere of the sec
tion was quantified by creating anatomically specific ROIs based on TH
immunolabeling and reference to a coronal atlas of the mouse brain
(Allen Brain Atlas). All images were obtained and analyzed under the
same conditions for magnification, exposure time, LED intensity, camera
gain and filter settings.
For quantitative assessment, TH+ and NeuN+ soma from the
selected areas determined by the ROI parameters were semiautomatically counted by adaptive thresholding in the Count and
Measure feature on the Olympus CellSens platform. Object filters for
cellular perimeter size, minimum and maximum area, and shape factor
thresholding were applied. Quantitative stereology analysis using the
motorized stage method was performed as descried (Tapias and
Greenamyre, 2014).
Caudal striatal sections containing the ST and the globus pallidus
(GP) were stained dually or triply including TH as the main marker of
interest. All slides were stained and imaged simultaneously to reduce
variability in intensity measurements. Whole brain montaging was
performed using a 10× Olympus X-Apochromat air objective (0.04 N.
A.). ROIs specific to the individualized striatal anatomical brain region
were applied and total average fluorescence intensity was determined
by manual threshold masking within the CellSens platform. Represen
tative whole brain montage images were generated using the 10× air
objective and high magnification inserts were acquired using the
Olympus X-Apochromat 100× oil objective (1.4 N.A.).

2.4. Tissue extraction and fixation
Based upon initial pilot studies of rotenone-induced neuro
degeneration in the SNpc, it was determined that a timepoint of 14 days
or 2 weeks post initial injection (2 WPI) directly following the conclu
sion of the rotenone exposure would represent the first time-point for
neuropathological analysis. Groups of mice were also evaluated each
week for an additional two weeks (3 and 4 WPI, respectively) to identify
neuropathological changes associated with progressive neuro
inflammation following rotenone exposure. Mice (n = 4/control group,
n = 7/rotenone group) were euthanized by isoflurane anesthesia fol
lowed by cardiac puncture. Perfusion-fixation was immediately per
formed using 20 mL of 0.1 M phosphate buffered-saline sodium
cacodylate buffer supplemented with heparin followed by 20 mL of 4%
paraformaldehyde. Brain tissue was carefully removed once fully
perfused and post-fixed in 10% neutral buffered formalin for two weeks
at room temperature. The tissue was then dissected for cassette prepa
ration, paraffin embedding, sectioning and histological examination.
2.5. Tissue preparation and automated high-throughput
immunofluorescent staining
Paraffin embedded brain tissue was sectioned at 6 μm thickness and
mounted onto poly-ionic slides (Histotox Labs, Boulder, CO). Slides were
deparaffinized and immunofluorescently labeled using a Leica Bond
RXm automated robotic staining system. Antigen retrieval was per
formed by using Bond Epitope Retrieval Solution 1 and 2 for 20 min in
conjunction with heat application. Sections were then incubated with
primary antibodies diluted in 0.1% triton-X containing phosphate
buffered saline (PBS): rabbit tyrosine hydroxylase (TH; Millipore;
1:500), mouse neuronal nuclei (NeuN; Millipore, 1:100), mouse glial
acidic fibrillary protein (GFAP, Cell Signaling, 1:100), rabbit S100β
(Abcam; 1:750), rat complement C3 (Abcam; 1:250), goat ionized cal
cium binding adaptor molecule 1 (IBA1; Abcam; 1:50), and mouse antialpha synuclein phosphorylation at serine position 129 (p129; Wako;
1:100). Sections were stained for DAPI (Sigma) and mounted on glass

2.8. Skeletonization and determination of microglial cell phenotype
Skeletonization analysis was performed as previously described
(Morrison et al., 2017). In brief, five randomized 400× images spanning
the entirety of the substantia nigra pars reticulata (SNpr) were taken
using a Olympus X-Apochromat 40× air objective (0.95 N.A). Image
software (National Institutes of Health, Version 1.5a) and appropriate
plug-ins (FFT bandpass filter, unsharp mask, and close) were down
loaded and applied to each of the images prior to converting to binary
and skeletonized images. Cell soma quantification was obtained by
3
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counting DAPI positive nuclei that co-localized with IBA1 cytoplasmic
staining. The Analyze Skeleton Plugin (developed and maintained by
http://imagej.net/AnalyzeSkeleton3) was applied to all the skeleton
ized images. DAPI-positive nuclei were measured using the straight-line
tool in order to determine a minimum positive threshold length that a
respective generated data point had to meet to be considered in the data
set allowing only for the counting of cells within the representative Zplane counting frame. Data was then compiled and filtered further by
endpoint number and threshold sizing. Microglia soma counts were then
used to determine microglial branches/cell, branch length/cell and
microglial junctions/cell.

analysis and identification of cells using the Deep Learning module
(v3.1). Training labels were created on a total of 8 sections across 4
control animals to train the artificial intelligence (AI) algorithm what a
‘positive event’ is (e.g., a cell), based on area, diameter, circumference,
fluorescence intensity, multiple channel intensity ratios and cellular
elongation factor. After 250 training labels were created spanning all
animals and ROIs, neural networking generation was performed on
standard basis with a total of 25,000–50,000 iterations including
cellular identification based on fluorescence intensity of S100β+ cells
and DAPI intensity, with exclusion of background tissue architecture
and intensity. Therefore, identification of astrocytic cells was made only
possible if all criteria were met. The network was deemed adequate at
the iteration where the similarity score was ≥0.80. Total objects within
each ROI were detected and counted using the Count and Measure
feature of Olympus CellSens where manual thresholding was applied to
accurately detect the AI identified S100β+ cells. Total cell counts were
then normalized to the total area of the ROI.

2.9. Semi-automated glial counting and intensity measurements within the
substantia Nigra and striatum
Methods used to quantify values of glial cells throughout brain re
gions were performed as previously described (Bantle et al., 2019). Two
total sections per animal were selected for glial counts based on
anatomical region and proximity to slides that were used to quantify
DAn values. The studies described herein were performed blinded by a
single investigator. Images utilized for quantification were captured
using an automated BX63 fluorescence microscope equipped with a
Hamamatsu ORCA-flash 4.0 LT CCD camera and collected using
Olympus CellSens software. Quantitative analysis was performed on
dual or triple-labeled fluorescent images through full brain montage
assessment. Each montage consisted of compiled individual 100× im
ages taken using an Olympus X-Apochromat 10× air objective (0.4 N.
A.). Dual hemispherical analysis was performed on active ROIs deter
mined by anatomical structures identified by immunofluorescent la
beling and referenced to the coronal mouse brain atlas (Allen Brain
Atlas). All slides were imaged and scanned using the same conditions of
exposure time, binning time, magnification, lamp intensity and camera
gain.
For identification of GFAP+ and IBA1+ cells, soma from the ROI
labeled areas were detected using semi-automated cell counting soft
ware on the CellSens platform. Total area of soma, fluorescent intensity,
mean grey intensity and cell shape object filters were used to determine
positive cells by manual adjustment to identify thresholding parameters
for accurate quantification of glial cells. Colocalization of S100β and
complement protein C3 (C3) was determined by using the colocalization function on the CellSens platform, channel minimum and
maximum were manually determined to ensure accuracy of dual label
identification. Pearson correlation coefficients were determined and the
colocalization algorithm was not accepted if the R value was below 0.85.
Two sections per animal were used to identify glial specific markers
within manually created ROIs, the total number of cells were then
divided by the overall area (mm2) of the ROI to allow for normalization
across dosing groups.
S100β and C3 colocalization was quantified by utilizing the colocalization feature within the Count and Measure module of CellSens.
Minimum and maximum intensity thresholds were manually deter
mined for each staining channel per individual section to account for
intensity variability between sections. Area of soma exclusion criterion
was applied following completion of the algorithm further selecting for
co-localized, dual-labeled cells. The number of infiltrating monocytes
were quantified based upon immunohistochemical staining and
morphological criteria as reported previously (Bantle et al., 2021).

2.11. Immunohistochemical staining and quantification of protein
aggregates
Sections were processed for histology and immunohistochemistry
using a Leica Bond-III RXm automated staining system according to the
manufacturer’s protocols. Antigen retrieval was performed in Bond
Epitope Retrieval Solution 1 and 2 for 20 min at 37 ◦ C. Reactive p129
cell/cell aggregates were stained using mouse monoclonal anti-phospho
Ser129 (P129) antibody (1:100, clone pSYN#64, WAKO) (Jang et al.,
2009). Immunoreactions and neuropathological scoring of P129+ pro
tein aggregates were conducted in the midbrain and ST on exposed and
unexposed brain sections by a veterinary pathologist blinded to the
exposure groups using scoring methodology that was adapted from
previous reports (Rey et al., 2016; Rey et al., 2018). We assessed the
presence of P129+ inclusions on two coronal sections per animal that
were 6 μm in thickness with an n = 4 control group/timepoint, n = 7
rotenone group/timepoint for each exposure group. Each section was
analyzed at a 10× and 40× magnification using an Olympus IX71 mi
croscope (Center Valley, PA) with Retiga 2000R (Qimaging, Surrey, BC,
Canada) and Qcolor3 (Olympus) camera and slidebook software (v6.0,
Intelligent Imaging Innovations, Inc., Denver, CO) for image acquisition
and analysis. A score of 0 to 5 was assigned to each brain region from a
single coronal brain section and scored as follows: 0 = no aggregation, 1
= very sparse/few (1–2) p129+ intra-cellular aggregates per cell per
high magnification field, 2 = mild (<10) p129+ intra-cellular aggre
gates per cell per high magnification field, 3 = moderate (<15) p129+
intra-cellular aggregates per cell per high magnification field, 4 =
marked (<20) p129+ intra-cellular aggregates per cell per high
magnification field, 5 = severe (>20) p129+ intra and extra cellular
aggregates per cell/surrounding cellular space per high magnification
field.
2.12. Proteinase K digestion of paraffin embedded tissue sections
Paraffin embedded tissue sections (6um) were ran on a Leica Bond
RXm automated robotic staining system. Sections were dewaxed and
epitopes were exposed using Leica Bond Epitope retrieval buffer 1.
Sections were then permeabilized and treated with 100μg/mL protein
ase K (pK, Roche) at 37 degrees Celsius for 30 min. This was followed by
serum blocking and primary antibody application. Sections that did not
receive pK received 1× tris-buffered saline incubations at 37 ◦ C for 30
min. Appropriate secondary antibodies were applied to the sections and
all images were obtained on an automated BX63 fluorescence micro
scope equipped with a Hamamatsu ORCA-flash 4.0 LT CCD camera and
collected using Olympus CellSens software. Sections that were previ
ously quantified for being high p129 aggregate yield through IF and IHC
pathological scoring were used as pK controls, to determine pK effec
tivity, along with absence of IBA1 and TH staining positivity.

2.10. Artificial intelligence-based identification of S100β+ astrocytes in
whole brain montage images
Whole brain montage images acquired at 10× magnification using
the same imaging parameters per section were utilized for quantification
of S100β+ cellular populations. Anatomical ROIs were hand drawn for
each section to encompass the SNpc and SNpr, per standard anatomical
landmarks (Allen Brain Atlas). Olympus CellSens software was used for
4
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2.13. Generation of representative normalized pathological overlays

determining the difference between the control subtracted experimental
infected values and the minimum overall value. The total obtained from
this calculation serves as the numerator. The range of the data set was
then determined by obtaining the difference from the minimum (y) and
maximum (z) values, this would serve as the denominator. The value
obtained from this overall calculation was then multiplied by 100 to
represent total percentage activation of each parameter. The respective
percentages at each time point (2, 3 and 4 WPI) were averaged and
plotted using spline curve fitting within GraphPad software (version
9.1.0; Graph Pad Software, San Diego, CA).

To generate the representative overlays at each time point, the total
number of DAn, microglia, macrophages, astrocytes cellular counts and
P129 pathological scores from infected mice were normalized to con
trols according to the following equation: ((x-y)/(y-z))*100 = normal
ized percentage value (Gopal Krishna Patro and Kumar Sahu, 2015). The
control values obtained for each pathological parameter were averaged
and then subtracted from the individual experimentally infected animal
values yielding a pathological representative of activation (x). The
minimum (y) and maximum (z) values were determined for each acti
vation parameter dataset. Normalization was then performed by

Fig. 1. Behavioral and locomotor changes within rotenone treated animals occur prior to Nf-kappaB activation. Open field tracking of C57/Bl6 behavioral patterns
through heat mapping and linear movement recognition, respectively, in control (A,B) and rotenone treated animals (C,D) show behavioral differences. Quantitative
analysis of changes in rest time (E), rearing number (F), margin time (G), and center time (H) are shown. (N = 4 control mice/group, N = 7 rotenone mice/group) NFkappaB-GFP-Luc dual reporter animals show increased levels of Nf-kappB luciferase photon flux beginning at 3 WPI (K) and increasing at 4 WPI (L). Whereas 2 WPI
(J) reflects that of control (I) levels. Rotenone exposure within these animals is sufficient enough to induce inflammatory activation and successive progression to the
4 WPI time-point (M). (2 WPI: n = 8 control, n = 9 rotenone; 3 WPI: n = 7 control, n = 7 rotenone; 4 WPI: n = 6 control, n = 5 rotenone).
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2.14. Nigrostriatal tract mapping

density that was more pronounced in the left hemisphere. Apoptotic
neurons were pyknotic and angular with decreased overall size, as well
as separated from the neuropil, leaving prominent pericellular clear
spaces.

Online access of Allen Brain Atlas mouse brain connectivity atlas
(https://connectivity.brain-map.org/) was utilized to identify source
search of substantia nigra (SNpc, SNpr) and target source of ST within
C57BL/6 J mice. Beta 3D browser-based atlas was then used to visualize
mouse anatomy and axial projection from database AAV injection
experiment number 100141993. Structural mapping was added with
visualization tools and view planes of the tract were downloaded.

3.2. Microglial activation and phenotypic profiling reveals dynamic M2M1 conversion in response to rotenone
Phenotypic conversion and pathological activation of microglia was
assessed by quantification of IBA1+ cell number and morphology within
the SNpc, SNpr, ST and GP (Fig. 2). Dual immunolabeling with IBA1 and
TH was used to identify microglial cell populations within DA brain
regions. Montage images of entire coronal brain sections were scanned
using a 10× objective and high-resolution images were acquired using a
100× objective. Representative baseline levels of microglia were present
in the SN, ST and GP of control animals (Fig. 2A, B). Exposure to rote
none resulted in increased microglial cell populations in the SNpc and
SNpr by 2 WPI (Fig. 2C), whereas the ST had minimal levels of microglial
hypercellularity at this timepoint (Fig. 2D). Microglial phenotyping
conducted at 2 WPI by skeletonization and filament tracing analysis
revealed conversion of resting/ramified microglia (M2) within the SN to
activated ameboid microglia (M1), characterized by reduction in branch
length, number of branches per cell and the total number of junctions
per cell (Fig. 2J, Q-S). At 3 WPI there was reduced activation and
recruitment of microglia in all brain regions examined, except for the
SNpr where increases in microglial cell population and activation states
were still present (Fig. 2E,F). Individual microglial cells within the SN
were seen retaining a M1 phenotypic state (Fig. 2K, Q-S), similar to the
activated amoeboid state observed at 2 WPI. By 4 WPI microglia showed
decreased activation and proliferation within the SNpc, SNpr, ST, and
GP (Fig. 2G, H), with a phenotypic return to a more ramified state
characterized by increased branch length, number of branches and
number of junctions per cell (Fig. 2L, Q - S). Quantification of the
number of microglia within each region over time was calculated by
semi-automated analysis of cells in designated ROIs encompassing
anatomically consistent sections within the SNpc (Fig. 2M), SNpr
(Fig. 2N), ST (Fig. 2O) and GP (Fig. 2P). Microglia were discriminated
from infiltrating peripheral macrophages by a previously established
protocol that differentiates based on size and morphological differences
and slides were read blinded by a pathologist (Smeyne et al., 2016). The
number of infiltrating macrophages was determined within the entire
SN and showed an increasing trend starting at 2 WPI and peaking at 4
WPI (Fig. 2T). Inter-regional normalization of IBA1 positive cells was
performed in each brain region relative to the start of rotenone exposure
to model the temporal changes in cellular number over time with respect
to the progression of rotenone-induced pathological changes. Regions
are denoted as follows (Fig. 2U): SNpc (pink), SNpr (cyan), ST (red), SN infiltrating macrophages (dashed green). Normalization of cellular re
sponses indicated that microglial reactivity peaked first in the ST at 2
WPI followed by the SNpr at 3 WPI, with a secondary increase in
microglia in the ST at 4 WPI. In contrast, the number of microglia in the
SNpc peaked between 2 and 3 WPI. Infiltrating macrophage numbers
within the SN increased steadily from 2 WPI to 4 WPI, coinciding with
the decrease of IBA1+ microglia within the SNpc and SNpr.

2.15. Statistical analysis
All data was presented as mean +/− SEM, unless otherwise noted.
Experimental values from each mean were analyzed with a ROUT
(alpha = 0.05) test to identify significant outliers and validate exclu
sions. Differences between time-exposure group was identified using a
two-way ANOVA, where individual timepoint comparisons between
exposure groupings were carried out using Sidak’s post hoc multiple
comparison test. Significance was identified as *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001. All statistical analysis was performed
using Prism (version 9.1.0; Graph Pad Software; San Diego, CA).
3. Results
3.1. Behavioral and locomotor deficits resulting from chronic rotenone
exposure in mice
Following optimization of rotenone dosing based on survival curve
analysis (Fig. 1A), the effects of subacute systemic rotenone exposure on
neurobehavioral function in C57Bl/6 mice were determined by openfield activity analysis. Heat maps (Fig. 1B,C) and linear pattern
tracking graphs (Fig. 1D,E) of behavioral function revealed anxiety-like
and depressive behavior and an overall reduction in exploratory
movement, with increased time spent towards the margins of the
chamber. Relative to individual baseline measurements, there were in
creases in rest time in mice exposed to rotenone compared to miglyolexposed control animals (Fig. 1F). There were also trens of decreased
rearing events from the rotenone animals at all timepoints, where the
parameter of time accounted for the most variance. There were also
decreases observed with the amount of time spent in the center of the
chamber at 1 WPI in the rotenone-exposed group (Fig. 1G,I), with a
corresponding increase in margin time (Fig. 1H) where the combination
thereof rotenone exposure and time accounted for significant variance
within regards to center time.
To determine the extent of neuroinflammation associated with
rotenone exposure, transgenic NF-κB-GFP-luciferase dual reporter mice
were administered rotenone for 14 days followed by two weeks of re
covery during which the bioluminescence signal of the NF-κB-luciferase
reporter was measured weekly. Following systemic administration of
rotenone, expression of the NF-κB reporter as determined by whole-body
bioluminescence imaging revealed an increase in reporter signal from 3
to 4 WPI (Fig. 1J-M). Total flux of photons per second was determined
for an equivalent region of interest (ROI) for each timepoint (Fig. 1N),
indicating an increasing linear trend in the rotenone exposed group
(Two-way ANOVA, p < 0.06, F(1,27) = 3.624) from 2 WPI to 4 WPI.
These findings were consistent with histopathological examination
of nigro-striatal nuclei performed by a veterinary pathologist at 2, 3 and
4 WPI with rotenone (Supplementary Fig. 1). This analysis revealed
focal neuronal apoptosis in the substantia nigra and caudate-putamen in
rotenone-treated animals compared to the control group, where affected
neurons appeared more angular and contained hyper-eosinophilic
cytoplasm. Pyknotic and karyolitic nuclei were present with focal glio
sis manifesting in occasional satellitosis and scattered Alzheimer Type II
astrocytosis. This was accompanied by multifocal gliosis within the ST,
especially within the striosomes, which exhibited axonal profile in
terruptions. By 4 WPI, the SN showed an overall decrease in neuronal

3.3. Rotenone toxicity induces a reactive A1 phenotype in astrocytes in
multiple brain regions
The changes in the inflammatory phenotype of astrocytes in response
to rotenone exposure was determined by quantifying the number of
S100β+ (Supplemental Fig. 2) and GFAP+ cells in concert with overall
fluorescence intensity of GFAP, as well as the number of cells coexpressing S100β and C3, a marker for A1 reactive astrocytes (Fig. 3).
In control animals, astrocytes displayed a resting stellate morphology in
all brain regions examined, without evidence of hypertrophy or other
features of inflammatory reactivity (Fig. 3A,B). By 2 WPI there were
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Fig. 2. Systemic administration of rotenone causes temporally and regionally distinct patterns of microglia activation. Microglial activation from an M2 phenotypic
state to an active ameboid M1 phenotype was investigated in control (A,B) and rotenone-treated animals at 2 WPI (C,D), 3 WPI (E,F) and 4 WPI (G,H) within the
substantia nigra and the ST, respectively (TH, green). Analysis of microglia phenotype by skeletonization and filament tracing was conducted in the SNpr in control
(I), 2 WPI (J), 3 WPI (K) and 4 WPI (L) animals. Quantification of IBA1+ cells (cyan) associated with microgliosis/microcytosis was performed within the SNpc (M),
SNpr (N), ST (O) and GP (P) at all timepoints. (Q-S) Changes in length of branches per cell (Q), number of branches per cell (R) and number of junctions per cell (S)
was also quantified at each timepoint. (T) The number of invading monocytes was quantified in the substantia nigra. (U) Normalized counts of IBA1+ cells in the
SNpc (pink), SNpr (cyan), ST (red) and invading macrophages within the SNpc (green dashed line) were modeled over the 4-week time course of the study. (N = 4
mice/control group, N = 7 mice/rotenone group) *p < 0.05, **p < 0.01, ***p < 0.001. (For interpretation of the references to colour in this figure legend, the reader
is referred to the web version of this article.)

Fig. 3. Rotenone exposure induces activation of astrocytes in the substantia nigra prior to the appearance of reactive A1 astrocytes in the striatum. Activation of
astrocytes (GFAP, red) within the substantia nigra (TH, green) and ST were investigated in control (A,B) and rotenone-treated mice at 2 WPI (C,D), 3 WPI (E,F) and 4
WPI (G,H). Astrocytosis/astrogliosis was quantified in the SNpc (I), SNpr (J), ST (K) and GP (L) at 2 WPI, 3 WPI, and 4 WPI. Cell number and intensity was normalized
to the respective control for each region to determine overall activation patterns throughout multiple brain regions at each timepoint. The number of A1 reactive
astrocytes was determined by immunolabeling and co-localization of S100β + C3 in the SNpc (M) and SNpr (N) for all timepoints. (O) Normalized GFAP intensity for
the SNpr (cyan), SNpc (pink) and ST (red) was modeling for all regions at each timepoint. (N = 4 mice/control group, N = 7 mice/rotenone group) *p < 0.05. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

increased numbers of hypertrophic GFAP+ cells in rotenone-treated
animals, primarily in the SNpc, with no increase detected in the SNpr,
ST or GP (Fig. 3C,D). This hypertrophy in GFAP+ cells was less evident
by 3 WPI in the SNpc and decreased further by 4 WPI (Fig. 3E,F and G,
H). Quantification of the number of GFAP+ cells and GFAP fluorescence
intensity in each brain region supported these observations (Fig. 3I,J);
two-way ANOVA analysis indicated a significant change in the number

of GFAP+ cells where rotenone exposure and time were parameters
investigated within the SNpc (p = 0.026, F(2,51) = 3.923) and GFAP+
intensity in the SNpr (p = 0.038, F(2,43) = 4.583). Expression of GFAP
in the SNpr increased from 3 WPI to 4 WPI, later than that in the SNpc.
The ST, interestingly, showed decreases in the number of reactive
GFAP+ astrocytes at 2 WPI (Fig. 3D), followed by levels similar to
control at 3 WPI and 4 WPI (Fig. 3F,H,K). In rotenone-exposed mice, the
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GP did not show any differences from that of control animals at any
timepoint investigated (Fig. 3L). The number of A1 astrocytes was
determined in each region by co-immunolabeling to identify cells posi
tive for expression of S100β and C3. The number of S100β+ cells coexpressing C3 did not change in the SNpc at any timepoint (Fig. 3M)
but increased in the SNpr at 3 WPI (Fig. 3N). Modeling normalized
changes in GFAP-expressing cells over time in the SN and ST indicated
peaks in A1 astrocytes in the SNpc occurring early at 2 WPI, followed by
the SNpr and ST at 3 WPI (Fig. 3O).

2013) (Fig. 4). Imaging of DAn within the SNpc of control animals
showed healthy neuronal cells forming a densely populated layer pro
jecting to an intact neuropil, as well as intact DA terminals in the ST
(Fig. 4A,B). By the end of rotenone exposure (2 WPI), there were evident
deprecations in neuronal integrity and prevalence in the SNpc, without
clear changes in TH staining in the ST (Fig. 4C,D). At 3 WPI, neurons
began to decrease in radial size and lose morphological integrity,
including loss of dendritic branching, decreased axon size and the
appearance of cells with pyknotic nuclei. (Fig. 4E). Increases in the in
tensity of TH+ DA terminals in the ST also became evident by 3 WPI
(Fig. 4F). By the second week following the end of rotenone exposure (4
WPI), there was clear loss of DA neurons within the SNpc with pro
gressive neurodegeneration characterized by decreases in the diameter
of neuronal soma, loss of morphological integrity and an increase in the
number of remaining cells that had pyknotic and fragmented nuclei
(Fig. 4G). Striatal terminal integrity largely decreased at 4 WPI, with
progressive loss of terminal intensity compared to the end of rotenone
exposure at 2 WPI (Fig. 4H). Quantification of the number of TH+

3.4. Rotenone exposure causes progressive loss of dopaminergic neurons
and projecting striatal fibers
To determine the extent of neuronal loss in response to systemic
administration of rotenone in C57Bl/6 mice, the number of neurons in
multiple brain regions were assessed by quantitative stereology using
scanning fluorescence microscopy of whole-brain sections coupled to
semi-automated image analysis as described previously (Tapias et al.,

Fig. 4. Rotenone induces selective loss of dopaminergic neurons in the substantia nigra pars compacta occurs that follows maximal inflammatory activation of glial
cells. The number of DAn (TH, green) and total neurons (NeuN, cyan) in the substantia nigra was examined by quantitative stereology in control (A) and rotenonetreated mice at 2 WPI (C), 3 WPI (E), and 4 WPI (G). The intensity of TH+ DAn terminals within the ST was also determined at each timepoint (B,D,F,H). (I)
Quantification of the number of DAn and (J) dopaminergic terminals in the ST. The number of NeuN+ neurons was quantified in the hippocampus, entorhinal cortex
and SNpc at 2 WPI (K), 3 WPI (L), and 4 WPI (M). (N = 4 mice/control group, N = 7 mice/rotenone group) *p < 0.05, ****p < 0.0001. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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neurons in the SNpc and the intensity of TH staining in the ST confirmed
these observations (Fig. 4I,J), indicating an approximate 35% loss in DA
neurons, most of which occurred in the two week lesioning period
following the end of rotenone administration.
To determine if neurodegeneration was specific to TH+ neurons in
the SNpc or generalized throughout the brain, NeuN staining was used to
examine the total number of neurons in multiple brain regions. Total
neuronal counts within the SNpc were unchanged at 2 WPI, indicating
that no neurodegeneration had yet occurred after two weeks of rotenone
exposure (Fig. 4K). Likewise, no loss of NeuN+ cells was detected in
either the hippocampus or entorhinal cortex at this timepoint. However,
during the lesioning period from 3 to 4 WPI with rotenone, there was a
significant and progressive decrease in the total number of NeuN+ cells
within the nucleus of the SNpc (p < 0.001 for rotenone exposure, F
(1,81) = 34.72). No change in the number of NeuN+ cells was detected
in the hippocampus or entorhinal cortex during the same period (Fig. 4L,
M).
3.5. Rotenone exposure induces the formation of proteinase K-resistant

α-synuclein aggregates

Alpha-synuclein aggregation and vacuolization is a hallmark of PD
and is an important determinant of disease progression (Mehra et al.,
2019). To characterize the formation and spread of p129 aggregates in
response to rotenone exposure, immunohistochemical staining and
pathological scoring of p129 was conducted in the SNpc and ST. Path
ological scoring of the extent of aggregate formation was conducted by a
veterinary pathologist using a ranking scale ranging from 0 to 5 ac
cording to the following metrics: 0 = no aggregation, 1 = very sparse/
few (1–2) p129+ intracellular aggregates per cell per high magnification
field, 2 = mild (<10) p129+ intracellular aggregates per cell per high
magnification field, 3 = moderate (<15) p129+ intracellular aggregates
per cell per high magnification field, 4 = marked (<20) p129+ intra
cellular aggregates per cell per high magnification field, 5 = severe
(>20) p129+ intra and extra cellular aggregates per cell/surrounding
cellular space per high magnification field. Three dimensional maps of
the nigro-striatal tract showing neuronal connectivity (highlighted in
white) were generated using the pathway mapping feature of the Allan
Brain Atlas (Fig. 5A,B). Region-specific analysis did not show significant
increases in p129 accumulation at the 2 WPI timepoint within the SN
(Fig. 5E, K) but did show increases in the p129 staining within the ST, as
noted by change in pathological score (Fig. 5F, L) compared to control
animals (Fig. 5C,D). Interestingly, at 3 WPI there was increased p129
aggregation in the SN (Fig. 5G, K) and a corresponding decrease within
the ST (Fig. 5H, L). By the 4 WPI timepoint there was further accumu
lation of p129 aggregates in the SN and elevation in the pathological
score within the ST above that of controls (Fig. 5I-L). The most promi
nent difference in misfolded protein occurred two weeks after the end of
rotenone exposure (4 WPI), with the appearance of intensely staining
intracellular aggregates of p129-Syn in neuronal perikariya, with addi
tional staining evident in glial cells surrounding p129+ neurons.
To further investigate cellular responses to accumulation of p129
aggregates within individual brain regions, we used immunofluores
cence imaging to detect the presence of p129 aggregates within both
DAn and microglia in the SN and ST (Fig. 6). Overall accumulation of
p129 was measured within the SNpc, SNpr and ST at each timepoint
(Fig. 6A-H). In control animals, little to no staining for p129 was
detected in neuronal soma or in surrounding microglia, which were few
in number and displayed a reticulated resting phenotype (Fig. 6A,E).
From 2 WPI at the conclusion of rotenone exposure to 4 WPI, progressive
increases in intracellular p129 were evident as intracellular puncta
within both TH+ neurons and microglia in the SN (Fig. 6B-D), as well as
in TH+ fibers and microglia in the ST (Fig. 6F-H). Quantification of total
p129 fluorescence intensity by brain region indicated that p129+ ag
gregates increased in the ST by 3 WPI, before the increase observed in
the SN at 4 WPI (Fig. 6I-K). Levels of p129 in microglia increased at 4

Fig. 5. Pathological scoring of alpha-synuclein aggregates in the substantia
nigra and striatum following systemic administration of rotenone. (A,B) Three
dimensional models of neuronal connectivity (white) in the nigro-striatal
pathway with spatial orientation to the olfactory bulb (OB) were generated
from the Allan Brain Atlas. Paraffin-embedded sections were immunolabeled
for phospho-(Ser129)-⍺-synuclein (p129) evaluated by blinded pathological
scoring for the severity of aggregate formation in the SN and ST in control (C,D)
and rotenone-treated animals at 2 WPI (E,F), 3 WPI (G,H) and 4 WPI (I,J).
Quantitative comparison of pathological scores for the SN (K) and ST (L) for
control and rotenone-treated animals was performed at each timepoint. (N = 4
mice/control group, N = 7 mice/rotenone group) *p < 0.05, ****p < 0.0001.
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Fig. 6. Formation and trafficking of alpha-synuclein protein aggregates in neurons and microglia following rotenone exposure. Accumulation of p129 was deter
mined in the ST and SNpc in control (A,E) and rotenone-treated animals at 2 WPI (B,F), 3 WPI (C,G) and 4 WPI (D,H). Representative images of brain sections
immunnolabeled for p129 aggregates (p129, pink), microglia (IBA1, cyan) and dopaminergic neurons and terminals (TH, green) are depicted for respective brain
regions at each timepoint. Overall intensity measurements of p129 accumulation were determined within the SNpc, SNpr and ST at 2 WPI, 3 WPI and 4 WPI in the
SNpc (I), SNpr (J) and ST (K). Co-localization of p129 aggregates in microglia was determined at each timepoint in the SNpc (L), SNpr (M) and ST (N). The intensity of
p129 aggregates in DAn was also determined at each timepoint (O). (P) The overall fluorescence intensity of p129 was plotted for each brain region over time to
established a normalized pathological model of disease progression. (N = 4 mice/control group, N = 7 mice/rotenone group) *p < 0.05, **p < 0.01, ***p < 0.001.
(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

WPI in the SN but were unchanged in the ST at the timepoints evaluated
(Fig. 6L-N). In TH+ neurons, p129 aggregates detected as fluorescence
puncta in peri-nuclear regions were elevated over control at all time
points (Fig. 6O). Normalized expression of overall p129 expression was
modeled within the brain regions, indicating peak accumulation within
the SNpr at 2 WPI followed by the ST at 3 WPI and a bimodal increase
within the SNpc at 2 and 4 WPI (Fig. 6P).
Proteinase K (pK) digestion studies were performed to determine the
stability of protein aggregates detected in the SN in rotenone-exposed
animals to proteolytic degradation (Fig. 7). In brain sections from con
trol animals very little aggregated p129 was detected in the SN by 4 WPI,
seen as a lack of staining intensity following digestion with pK, which
fully degraded the intact TH epitope (Fig. 7A). In brain sections from
rotenone-exposed animals subjected to pK digestion, intense staining for
p129 was still evident (Fig. 7B) that co-localized with TH+ DAn, as seen
in companion sections not incubated with pK (Fig. 7C). High resolution
microscopic analysis revealed the presence of largely intracellular
puncta within DAn in the SNpc that gradually accumulated from 2 to 4
WPI, with the highest levels occurring at latest timepoint evaluated. At
this timepoint, p129+ puncta were present throughout the neuronal
perikaryon as well as in neighboring microglia (Fig. 7D-H). A similar
pattern of accumulation was detected in TH+ fibers in the ST, which
peaked at 3 WPI and were similarly present within surrounding micro
glia (Fig. 7I-M). Microglial trafficking and dissemination of p129+ ag
gregates was also investigated, revealing IBA1+ cells located within the
corpus callosum (Fig. 7S), peri-vascular areas (Fig. 7T), choroid plexus
(Fig. 7U), third ventricle (Fig. 7U) and migrating along TH+ projecting
neuronal fibers within the nigro-striatal pathway (Fig. 7V), as well as
localized to peri-nuclear regions of the cell. There was a relative paucity
of microglia in control animals in these brain regions and none that
contained P129+ aggregates (Fig. 7N-R).

4. Discussion
Rotenone has been used successfully to model multiple pathological
features of PD, most notably in Lewis rats, where intraperitoneal
administration induces behavioral deficits, loss of DA neurons, degen
eration of striatal terminals and p129 aggregation (Betarbet et al., 2000;
Cannon et al., 2009; Zeng et al., 2018). Studies attempting to adapt this
model to mice have suffered from a number of limitations, including
high mortality rates and a necessity for increased sample size due to
systemic toxicity (Duty and Jenner, 2011). Additionally, translating
doses of rotenone from rats to mice has proven challenging due to the
two- to three-fold higher metabolic expenditure on a per gram basis in
mice compared to rats (Radermacher and Haouzi, 2013). In mammals,
the parent molecule, (2R, 6aS, 12aS)-1,2,6,61,12,12a-hexahydro-2-iso
propenyl-8,9-dimethoxychromeno[3,4-b]furo(2,3− h)chromen-6-one, is
a potent mitochondrial complex I inhibitor, whereas the rotenone me
tabolites are 4-fold less toxic, underscoring the importance of species
differences in expression of drug metabolizing enzymes that influence
dosing with rotenone (Fukami et al., 1969). In addition, typical routes of
administration such as oral gavage, inhalation, environmental-contact,
and unilateral stereotactic injection are laborious and prone to varia
tion in dosage between individual subjects (Inden et al., 2007; Inden
et al., 2011; Liu et al., 2015; Pan-Montojo et al., 2010; Rojo et al., 2007;
Wang et al., 2020). In the present study, we show that daily adminis
tration of rotenone to mice by intraperitoneal injection for 14 days re
sults in low mortality, marked activation of glial cells, formation of
p129+ aggregates and progressive neurodegeneration, all of which
reaches a maximum during the two-week period following rotenone
exposure. The progression of neuropathology during this post-rotenone
lesioning period was characterized by behavioral changes, DAn loss,
increased glial cell activation, recruitment of peripheral monocytes and
the appearance of p129 inclusions similar to that seen in idiopathic PD
(Cheng et al., 2010).
Behavioral changes such as depression and anxiety are common nonmotor symptoms of PD and precede the onset of motor symptoms. These
early neuropsychiatric changes can manifest from alterations in dopa
minergic, serotonergic, cholinergic and adrenergic neurotransmission
(Belovicova et al., 2017; Gallagher and Schrag, 2012; Shiba et al., 2000).
Interestingly, mice that were exposed to rotenone presented with anxi
ety and depressive-like behaviors in open field assays at 1 WPI, evi
denced by an increase in margin time and rest time and decreased in
center time and rearing number (Fig. 1). Following this timepoint, the
increase in luciferase signal in NF-κB-GFP-luciferase reporter mice
indicated an overall progressive increase in neuroinflammation, similar
to the spread of dystrophic, inflammatory microglia observed in idio
pathic PD (Braak et al., 2007; Yao et al., 2021) and in rat models of
rotenone-induced PD (Betarbet et al., 2000; Cannon et al., 2009).
Key cytopathological features of PD, such as mitochondrial
dysfunction, p129 synuclein accumulation, neuroinflammation and
oxidative stress (Schapira and Jenner, 2011), are not all reproduced in
many mouse models of the disease. Mitochondrial dysfunction and ag
gregation of p129 are thought to drive activation of glia and progressive
neurodegeneration, but many toxin-based and genetic models lack both
of these important phenotypic features of PD in the SN (Lucking and
Brice, 2000; Robinson, 2008; Xie et al., 2010). In this murine model of
rotenone-induced PD, histopathological examination of treated mice
revealed progressive glial cell activation within the nigro-striatal

3.6. Glial-glial and glial-neuronal interactions mediate the progression of
protein misfolding and neuronal injury following exposure to rotenone
The overall progression of pathological changes in the nigro-striatal
pathway following systemic administration of rotenone for two weeks
was modeled in Fig. 8. Three dimensional pathways were overlayed with
region-specific changes in microglial activation, p129 accumulation,
astrocyte activation and loss of DA neurons, presented as a longitudinal
model to depict connectivity of these pathological alterations between
brain regions (Fig. 8A). This mapping approach indicates temporal,
regional and cellular specificity with respect to the pathology induced
by systemic exposure to rotenone. Within the SNpc, GFAP expression
and initial accumulation of p129 aggregates were seen by the end of
rotenone exposure at 2 WPI. This was followed by a peak of microglial
cell increase at 3 WPI that coincided with a decrease in p129+ aggre
gates and loss of DAn in this brain region (Fig. 8B). In the SNpr there was
a similar early increase in p129 by 2 WPI, followed by the peak of
microglia activation and A1 astrocyte reactivity at 3 WPI (Fig. 8C). The
ST displayed an initial peak of microglia activation at 2 WPI followed by
p129 aggregation at 3 WPI and then A1 astrocyte activation and
degradation of DA terminals at 4 WPI (Fig. 8D). Schematic representa
tion of all brain regions spanning the post-rotenone lesioning periods
reveals specific cellular responses and activation in association with
movement and accumulation of p129 leading to neurodegeneration
(Fig. 8E).
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Fig. 7. Microglia clear proteinase K-resistant α-synuclein aggregates in the brains of rotenone-treated mice. (A-C) High resolution hemispheric montage images of
pK-digested brain sections from control (A) and rotenone-treated (B) animals, as well as a representative section from a rotenone-treated animal (− )pK digestion at 4
WPI (C). TH (green), p129 (pink) and IBA1 (cyan). High magnification images of pK-digested brain sections from control (D,I) and rotenone-treated groups at 2 WPI
(E,J), 3 WPI (F,K) and 4 WPI (G,L). (H,M) 4 WPI rotenone-treated tissue without pK digestion. By comparing control (N-R) and rotenone-treated (S-W) brain tissue
immunolabeled for IBA1, p129 and TH, IBA1+ cells were identified trafficking intracellular p129+ aggregates in rotenone-treated brains within the corpus callosum
(S), peri-vascular areas (T), choroid plexus (U), third ventricle (V) and nigro-striatal pathway (W). (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
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Fig. 8. Modeling the progression of cytopathological changes in the nigro-striatal pathway following systemic exposure to rotenone. (A) Three dimensional pathways
depicting neuronal connectivity were overlayed with region-specific changes at each timepoint for microglial activation, p129 accumulation, astrocyte activation and
loss of DA neurons. Following two weeks of rotenone exposure, microglia activate initially in the ST, whereas activation of astrocytes and formation of p129 ag
gregates occurs first in in the SN, spreading thereafter to the ST. By 4 WPI these changes in glial phenotype and protein aggregation lead to loss of DAn in the SNpc.
Changes in individual parameters were modeled to accurately depict normalized temporal changes in pathological features for the SNpc (B), SNpr (C) and ST (D). (E)
Summary schematic representing cell-cell interactions, aggregation and trafficking of p129 and neurodegeneration for all brain regions over time.

system. This activation was associated with neuronal resection from the
neuropil, overall cellular loss, gliosis, ventricular edema and multifocal
myelinic edema advancing from 3 to 4 WPI (Supplementary Fig. 1).
Importantly, changes in astrocyte reactivity and phenotype in response
to systemic exposure with rotenone occurred prior to neuronal loss in
the brain regions evaluated, consistent with the appearance of reactive,
p129+ astrocytes in idiopathic PD (Braak et al., 2007).
Reactive, dystrophic microglia appear prior to the majority of neu
rodegeneration in both PD and Lewy Body disease (Doorn et al., 2014).
Microglial cells act as resident innate immune cells in the CNS,

whereupon encountering pathogens or toxins, they quickly convert from
a resting M2 state to a pro-inflammatory M1 state. M1 microglia are
characterized by production of ROS and inflammatory cytokines such as
TNF-α, IL-6, IL-12, IL-1beta and CCL2 (Subramaniam and Federoff,
2017). These early innate inflammatory immune responses have been
detected in PD patients as increased cerebrospinal fluid levels of IL1beta, IL-6 and human leukocyte antigen-DR isotype reactive micro
glia (Blum-Degen et al., 1995; McGeer et al., 1988). Notably, a study
employing chronic exposure of C547Bl/6 mice to low levels of rotenone
in diet reported increases in the astrocyte-derived cytokine, CXCL1, as
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well as IL-1beta, that were diminished in mice deficient in NLR Family
Pyrin Domain Containing 3 (Nlrp3), a key mediator of innate immunity
in microglia (Martinez et al., 2017). In the present study, increases in
both the number of microglia and the fraction of microglia displaying an
M1 phenotype was seen within the SNpr and SNpc at 2 WPI in response
to rotenone exposure (Fig. 2). Microglia remained activated at the 3 WPI
timepoint, with a gradual return to a more resting, M2-like phenotype by
4 WPI (Fig. 2). Following rotenone exposure, there was an apparent
increase in peripheral macrophages in the SN that peaked at 4 WPI,
although this trend will require a greater number of animals to validate
appropriately. This has also been reported in post-mortem PD tissue
(Fuzzati-Armentero et al., 2019). Infiltration of peripheral monocytes is
likely mediated by disruption of blood-brain-barrier (BBB) integrity due
to cytokines and chemokines released from M1 microglia (Salvi et al.,
2017). This infiltration and recruitment of macrophages aids in the
clearance of p129 aggregates but also increases inflammatory activity
and worsens the overall disease state.
Similar to the phenotypic responses observed in microglia, there was
an increase in the number and reactivity of astrocytes in the nigrostriatal system that followed the peak of microglia activation in each
brain region and coincided closely with the maximum extent of p129
aggregate formation. We observed an initial peak in hypertrophic,
GFAP+ cells expressing C3 at 2 WPI in the SNpc and overall regional
decreases in total S100β + cell populations in the SNpc and SNpr, fol
lowed by an increase in C3+ astrocytes within the striatum and increased
populational distribution of astrocytes within the SNpr at 3 WPI (Fig. 3,
Supplementary Fig. 2). C3 is reported to be a marker for reactive,
neurotoxic A1 astrocytes (Liddelow et al., 2017) that is induced in
response to C1q and IL-1alpha released by M1 microglia (Wei et al.,
2021). Intra-astrocytic C3 processing to C3a is followed by extra-cellular
release and recognition by C3aR on microglia, thus reinforcing glial-glial
interactions that amplify neuronal injury (Wei et al., 2021). In PD,
activated astrocytes are seen in the SN in areas of DA neuron loss
(Middeldorp and Hol, 2011), as we also noted in rotenone-treated mice.
The initial appearance of reactive astrocytes in the SN at 2 WPI coin
cided with the peak of p129 in the SNpc (Fig. 6) and was followed by the
peak of C3-expressing astrocytes in the striatum at 3 WPI. This suggests
that rotenone-induced mitochondrial dysfunction occurs initially in the
SN and drives innate immune activation of glial cells and protein ag
gregation in this brain region.
Stereological analysis revealed DAn loss within the SNpc and striatal
terminal loss by 4 WPI (Fig. 4), similar to the pattern of DAn loss seen in
idiopathic PD (Michel et al., 2016). Notably, loss of DAn was not
observed following rotenone exposure at 2 WPI but occurred two weeks
later (4 WPI), after the appearance of reactive microglia and astrocytes
in the SNpc. This strongly supports the assertion that innate immune
activation of glia is an important mediator of neuronal injury during
exposure to rotenone. Loss of TH+ terminal density in the striatum also
occurred at 4 WPI but, interestingly, was preceded by an increase in TH
intensity within the striatum at 3 WPI (Fig. 4). Tyrosine-hydroxylase is
the rate limiting enzyme of catecholamine biosynthesis and its expres
sion is modulated by the redox-sensitive proteins, DJ-1 (PARK7), which
is up-regulated by oxidative stress, such as that caused by inhibition of
complex I by rotenone (Ariga et al., 2013; Zhong et al., 2006). This may
at least partly explain the apparent transient increase in TH intensity in
the striatum observed at 3 WPI in rotenone-treated mice. The regional
selectivity of rotenone-induced neuronal loss within the basal ganglia
was assessed by determining the number of NeuN+ neurons in the hip
pocampus and entorhinal cortex, which did not show loss of neurons
compared to the SNpc (Fig. 4). Because rotenone is a systemic complex I
inhibitor, these data indicate that dopaminergic neurons within the
SNpc are selectively vulnerable to complex I inhibition in C57Bl/6 mice.
Formation of Lewy bodies in DA neurons in the SNpc is one of the
central pathological features of PD but is difficult to replicate in most
murine models of the disease. Because previous studies using intraper
itoneal administration of rotenone in male Lewis rats reported

accumulation of p129 in DAn in the SNpc (Sherer et al., 2003), we
examined the formation of synuclein aggregates using immunostaining
for the phosphorylated form of the protein (phospho-Serine129-⍺-syn
uclein) in rotenone-treated mice (Figs. 3 and 4). There was increased
formation of p129+ puncta within TH neurons beginning at 3 WPI and
progressing to 4 WPI. The size and intensity of these aggregates within
microglia varied amongst brain region and timepoint (Fig. 6), suggesting
that microglial clearance via the autophagy pathway is an important
modulator of the neuronal burden of p129. Interestingly, rotenone re
duces autophagy of p129 aggregates in DAn that is rescued by over
expression of DJ-1 (De Miranda et al., 2018), highlighting the
importance of microglial clearance of p129+ aggregates in limiting
neuronal injury. The kinetics of p129+ aggregate formation in response
to rotenone suggests that this mouse model is relevant to understanding
mechanisms underlying the alterations in autophagy and protein pro
cessing associated with the progression of PD (Lynch-Day et al., 2012;
Pan et al., 2008).
Alpha-synuclein has been investigated as a potential biomarker for
PD due to its presence in the blood and CSF of PD patients (Chang et al.,
2019; El-Agnaf et al., 2003; Gao et al., 2015). However, the mechanism
of clearance from the CNS by glial cells is not fully understood (Choi
et al., 2020). Because microglial cells are long-lived and perform critical
phagocytic functions in the CNS (Hefendehl et al., 2014), they are likely
important modulators of p129 clearance. Data from rotenone-treated
mice in these studies supports this mechanism, where IBA1+ cells con
taining p129+ aggregates were identified in perivascular regions and
along projecting fibers of the nigro-striatal pathway, as well as within
the corpus callosum at 4 WPI (Fig. 7). Migration of p129+ microglia
along these routes in rotenone-treated mice is consistent with gliallymphatic clearance of p129 and elevated circulating levels of p129
seen in PD patients. Moreover, the resistance of p129+ aggregates to
digestion by pK (Fig. 7) echoes the results of p129 self-seeding studies
reporting that recombinant fibrillar p129 aggregates were resistant to
pK digestion (Kushnirov et al., 2020). The presence of highly stable, pKresistant p129+ aggregates in rotenone-exposed mice is an important
pathological feature of this model that reproduces aspects of protein
misfolding observed in idiopathic PD (Angot et al., 2012; Kordower
et al., 2008; Lee et al., 2010; Li et al., 2008). Notably, the presence of pKresistant p129+ aggregates resembles the pattern of p129 aggregation
we recently reported in virally-induced parkinsonism in mice (Bantle
et al., 2019; Bantle et al., 2021). Additional studies will be required to
determine more precisely the role of microglia autophagy pathways in
modulating levels of p129+ aggregates in rotenone-treated mice.
These findings reveal a complex temporo-spatial progression of
neuropathology in rotenone-induced parkinsonism involving numerous
cell types, cell-to-cell signaling mechanisms and differential suscepti
bility amongst nigro-striatal brain regions. In addition, distinct patterns
of p129 aggregation, movement of these aggregates along inter
connected neural tracts and glial clearance all appear to influence the
progression of pathology. The summary model of rotenone-induced
neuropathology presented here (Fig. 8) highlights the relationship be
tween both temporal and spatial patterns of glial activation and p129
aggregation that lead to the loss of DAn within the SN. Early peaks of
glial activation seen in the ST and SN after 2 WPI with rotenone resulted
in rapid accumulation of pK-resistant p129+ aggregates in these brain
regions, which were followed by progressive loss of DAn in the SNpc
(Fig. 8). Interestingly, p129+ aggregates were seen within projecting
TH+ fibers of the nigro-striatal tract and in M1 phagocytic microglia
surrounding DAn in the SNpc, suggesting that distribution of p129 in
rotenone-treated mice is heavily influenced both by inter-neuronal
spread and by glial clearance. The early appearance of reactive,
dystrophic glial cells and deposition of p129+ aggregates prior to the
majority of neuronal loss are features of this murine model of rotenoneinduced parkinsonism that compare favorably to the progression of
neuropathology in idiopathic PD (Braak et al., 2007). Moreover, the
rapid appearance of p129+ aggregates within weeks of systemic
15
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rotenone exposure increases the utility of this model for basic as well as
translational research. It will be important in future studies to determine
more precisely the role of glial activation in modulating the formation
and distribution of p129 following rotenone exposure in the basal
ganglia. It will also be important to examine the effects of rotenone on
additional brain regions involved with control of motor function to
better understand the pathology resulting from deprecations in mito
chondrial function in the brain. Studies will also need to delineate cellspecific changes in gene expression that regulate phenotypic switching
of glia to a reactive, neurotoxic state that negatively impacts neuronal
survival in the basal midbrain.
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